查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456961

全球抗体药物复合体市场：2024年至2029年预测

Global Antibody Drug Conjugates Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 210 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

抗体药物复合体市场预计将从 2022 年的 70.17 亿美元增至 2029 年的 388.85 亿美元，预测期内复合年增长率为 27.7%。

抗体药物复合体（简称 ADC）是设计用于癌症治疗的标靶治疗的生物药品。抗体药物复合体将单株抗体的特异性标靶特性与细胞毒性药物的抗癌能力结合起来，能够灵敏地区分健康组织和患病组织。 ADC 是三组分系统，其中有效的细胞毒性抗癌药物透过生物分解性的接头连接到抗体上。抗体与癌细胞表面的特定标记（抗原或受体）结合。在癌细胞内部，整个抗体-药物缀合物被内化，连接体被降解，释放出活性药物。

推动抗体药物复合体市场的主要成长要素是癌症盛行率的增加。癌症每年影响数百万人的生命，而且这个数字还在持续上升。开发有效治疗方法的需求从未如此迫切。此外，提高个人健康意识有助于及早发现癌症，以便及时治疗，避免癌症进一步扩散到身体其他部位。此外，增加癌症治疗的医疗保健支出以及增加 ADC 的研发在全球抗体药物复合体市场的成长中发挥着重要作用。此外，标靶化癌症治疗的全球趋势以及 ADC 研发的活性化也对市场做出了重大贡献。标靶治疗有助于消除癌细胞，而不会真正伤害健康细胞。

市场驱动力

  • 癌症患者增加

癌症患者的数量正在增加。癌症是全球第二大死因。根据世界卫生组织（WHO）估计，2018年全球将有960万人死于癌症。每年约有 40 万名儿童罹患癌症。人们对癌症的认识不断提高以及医疗机构的早期发现使得在癌症造成严重损害之前将其消灭成为可能。久坐的生活方式以及垃圾食物、烟草和酒精的消费量增加是导致癌症的常见因素。大约三分之一的死亡是由吸烟和饮酒、肥胖、水果和蔬菜摄入量低以及缺乏运动造成的。 2020年，最常见的死因是肺癌，其次是大肠癌和肝癌。肺癌造成 1.8 亿人死亡，大肠癌造成 9,350 人死亡，肝癌造成 83 万人死亡。乳癌也是最常见的癌症之一。早期发现和适当的治疗可以预防死亡。目前，30-50%的癌症患者是可以预防的。

  • ADC 研究和开发在世界各地变得越来越广泛。

随着各公司加强研发力度以寻找有效的癌症治疗方法，越来越多的公司正在投资研发来开发此类药物。随着认识的深入和新技术的出现，ADC研发的范围正在进一步扩大。此外，美国食品药物管理局（FDA）产品的核准率显着提高。 2021年，已有12个ADC药物核准。此外，正在深入研究 ADC 和免疫系统之间的相互作用，以寻找可能的协同治疗效果，从而可用于药物改进。

市场限制因素

  • 昂贵的治疗费用

癌症治疗需要花很多钱。这是由于该药物需要大量的研究、许可、专利和製造成本。根据世界卫生组织 (WHO) 统计，2010 年癌症造成的年度经济损失估计为 1.16 兆美元。抗体药物复合体对于癌症患者来说是昂贵的治疗方法，而用于研究和开发的时间和金钱也增加了成本。 ADC 的製造成本也较高，这会增加到最终模具中。原材料成本在製造过程中占主导地位。根据毒素的性质，药物粘合剂的原料价格在每克 200 美元到 2,000 美元之间。此外，如果每年只生产少量剂量，就无法实现规模经济。此外，药品监管部门的严格监管也推高了成本。

主要进展

  • 2023年7月－ImmunoBiochem与ImmunoGen签订了多标靶许可和选择权协议，以推进抗体药物复合体（ADC）的开发。此次合作将ImmunoGen 的接头和有效负载技术与ImmunoBiochem 的目标特异性抗体结合。免疫生物化学公司收到预付款，以换取现有抗体的独家许可。
  • 2023年7月——百济神州和 DualityBio 达成协议，获得针对固体癌患者的临床前 ADC 疗法的全球临床和商业许可的独家选择权。 DualityBio 将收到预付款和基于里程碑的额外付款，总合高达 13 亿美元。百济神州持有全球权利，而 DualityBio 将进行研究并支持未来的 IND 申请。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球抗体药物复合体市场：依产品类型

  • 介绍
  • ADCETRIS
    • 市场机会和趋势
    • 成长前景
    • 地理收益
  • 门头
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第六章全球抗体药物复合体市场：以标靶类型

  • 介绍
  • CD30抗体
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • Her2抗体
    • 市场机会趋势
    • 成长前景
    • 地域盈利
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第七章抗体药物复合体的全球市场：依技术分类

  • 介绍
  • 可切割接头
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 不可切割的接头
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第八章抗体药物复合体的全球市场：按应用

  • 介绍
  • 乳癌
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 血癌
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 泌尿道癌/膀胱癌
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 子宫颈癌和头颈癌
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第九章全球抗体药物复合体市场：依最终用户分类

  • 介绍
  • 医院
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 诊所
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 其他的
    • 市场机会趋势
    • 成长前景
    • 地理收益

第十章全球抗体药物复合体市场：按地区

  • 介绍
  • 北美洲
    • 依产品类型
    • 按目标类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 按目标类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 按目标类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 按目标类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 按目标类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区

第十一章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十二章 公司简介

  • The Linde Group
  • Astrazeneca
  • Pfizer, Inc
  • Seagen, Inc.
  • GSK Plc
  • Takeda Pharmaceutical Company Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Astellas Pharma
  • Daiichi Sankyo Company Ltd.
  • Genentech Inc.
  • Immunogen Inc.
  • Lantheus
  • Bayer Healthcare Pharmaceuticals
  • Astellas Pharma
  • Synthon Holding BV
简介目录
Product Code: KSI061612249

The global antibody drug conjugates market is projected to witness a CAGR of 27.7% during the forecast period to reach a total market size of US$38.885 billion by 2029, increasing from US$7.017 billion in 2022.

Antibody Drug Conjugates, or ADCs for short, are biological drugs designed as a targeted therapy for treating cancer. Antibody-drug conjugates provide sensitive differentiation between healthy and diseased tissue by combining the specific targeting of monoclonal antibodies with the cancer-killing capacity of cytotoxic medicines. ADC is a three-component system with a potent cytotoxin anticancer agent linked by a biodegradable linker to an antibody. The antibody attaches to certain markers on the cancer cell's surface (antigens or receptors). Within the cancer cell, the entire antibody-drug conjugate is internalized, where the linker is degraded and the active drug is liberated.

The key growth factor driving the antibody-drug conjugate market is the growing prevalence of cancer. Cancer affects millions of lives every year and is increasing. The need to develop an effective treatment is higher than ever before. Further, increasing health consciousness amongst individuals helps identify cancer in its early stages, which can be treated on time without any further spread of cancer to other parts of the body. Moreover, growing healthcare expenditure on cancer treatment and rising R&D in ADCs play an important role in the growth of the global antibody-drug conjugate market. Furthermore, the global trend toward targeted cancer therapeutics, as well as increased research and development on ADCs, are significantly contributing to the market. Targeted therapy helps to eliminate cancer cells without actually harming healthy cells.

MARKET DRIVERS

  • Patients with Cancer Are Increasing

Patients with cancer have seen an upward trend. Globally, cancer is the second largest cause of death. According to the World Health Organization, 9.6 million people are estimated to die due to cancer worldwide in 2018. Around 400,000 children develop cancer each year. With increasing awareness of cancer and rising, medical facility detection of cancer in its early stages, early detections help eliminate it before some serious damage is done. An increasingly sedentary lifestyle and increasing consumption of junk food, tobacco, and alcohol are some of the prevalent factors causing cancer. Around one-third of deaths are from cancer due to tobacco and alcohol use, obesity, low fruit and vegetable intake, and lack of physical activity. In 2020, the most common cause of death was lung cancer, followed by colon and rectum cancer, and liver cancer. Accounting for 180 million deaths by lung cancer, 9.35 thousand deaths due to colon and rectal cancer, and 830 thousand deaths due to liver cancer. Breast cancer is another of the most common types of cancer. With early detection and proper treatment, deaths could be prevented. Between 30-50% of cancer cases can currently be prevented.

  • ADC research and development is becoming increasingly extensive around the world.

With the increasing development in research and development by various companies to find an effective cancer treatment, more and more companies are investing in R&D to develop such drugs. With a deeper understanding and the advent of new technology, the scope of R&D in ADCs has further increased. Moreover, the approval rate for U.S. Food and Drug Association (FDA) products has increased significantly. In the year 2021, 12 ADC drugs have been approved. Further, deep research on interactions between ADCs and the immune system for potential synergistic therapeutic effects that can be used to improve the drug is taking place.

MARKET RESTRAINT:

  • Expensive Treatment

Cancer treatments come with a hefty price tag., due to extensive research, licensing, patents, and manufacturing costs of drugs. According to the World Health Organization (WHO), the total annual economic cost of cancer in 2010 was estimated at US$ 1.16 trillion. Antibody-drug conjugates can be an expensive treatment for cancer patients, with a high level of time and money invested in R&D adding to the cost. ADCs also have a high manufacturing cost, which adds up to the final cast. The dominant cost in the manufacturing process of raw materials. Depending on the nature of the toxins, the drug-linker raw material can cost between $200-$2000 per gram. Furthermore, a small batch of doses produced per year is not able to reach economies of scale. Further, strict regulation from medical and drug authorities adds to the cost.

Key Developments:

  • July 2023- ImmunoBiochem has signed a multi-target license and option agreement with ImmunoGen to advance antibody-drug conjugates (ADCs). The collaboration will combine ImmunoGen's linker and payload technologies with ImmunoBiochem's antibodies against specific targets. ImmunoBiochem will receive an upfront fee in exchange for an exclusive license to existing antibodies. The collaboration will focus on preclinical activities, with ImmunoGen responsible for clinical development and commercialization.
  • July 2023- BeiGene and DualityBio have agreed to acquire an exclusive option for a global clinical and commercial license for an investigational, preclinical ADC therapy for patients with solid tumors. DualityBio will receive an upfront payment and additional payments based on milestones, totaling up to $1.3 billion. BeiGene will hold global rights, while DualityBio will conduct research and support future IND filings.

Market Segmentation:

By Product Type

  • Adcetris
  • Kadcyla
  • Other Product Types

By Target Type

  • Cd30 Antibodies
  • Her2 Antibodies
  • Others

By Technology

  • Cleavable Linker
  • Non-Cleavable Linker

By Application

  • Breast Cancer
  • Blood Cancer
  • Urinary Tract/Bladder Cancer
  • Cervical And Head & Neck Cancer

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Adcetris
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Kadcyla
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Others
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE

  • 6.1. Introduction
  • 6.2. Cd30 Antibodies
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Her2 Antibodies
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Cleavable Linker
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Non-Cleavable Linker
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

  • 8.1. Introduction
  • 8.2. Breast Cancer
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Blood Cancer
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Urinary Tract/Bladder Cancer
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Cervical And Head & Neck Cancer
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY END-USER

  • 9.1. Introduction
  • 9.2. Hospitals
    • 9.2.1. Market Opportunities and Trends
    • 9.2.2. Growth Prospects
    • 9.2.3. Geographic Lucrativeness
  • 9.3. Clinics
    • 9.3.1. Market Opportunities and Trends
    • 9.3.2. Growth Prospects
    • 9.3.3. Geographic Lucrativeness
  • 9.4. Others
    • 9.4.1. Market Opportunities and Trends
    • 9.4.2. Growth Prospects
    • 9.4.3. Geographic Lucrativeness

10. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. By Product Type
    • 10.2.2. By Target Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End-User
    • 10.2.6. By Country
      • 10.2.6.1. United States
        • 10.2.6.1.1. Market Opportunities and Trends
        • 10.2.6.1.2. Growth Prospects
      • 10.2.6.2. Canada
        • 10.2.6.2.1. Market Opportunities and Trends
        • 10.2.6.2.2. Growth Prospects
      • 10.2.6.3. Mexico
        • 10.2.6.3.1. Market Opportunities and Trends
        • 10.2.6.3.2. Growth Prospects
  • 10.3. South America
    • 10.3.1. By Product Type
    • 10.3.2. By Target Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End-User
    • 10.3.6. By Country
      • 10.3.6.1. Brazil
        • 10.3.6.1.1. Market Opportunities and Trends
        • 10.3.6.1.2. Growth Prospects
      • 10.3.6.2. Argentina
        • 10.3.6.2.1. Market Opportunities and Trends
        • 10.3.6.2.2. Growth Prospects
      • 10.3.6.3. Others
        • 10.3.6.3.1. Market Opportunities and Trends
        • 10.3.6.3.2. Growth Prospects
  • 10.4. Europe
    • 10.4.1. By Product Type
    • 10.4.2. By Target Type
    • 10.4.3. By Technology
    • 10.4.4. By Application
    • 10.4.5. By End-User
    • 10.4.6. By Country
      • 10.4.6.1. United Kingdom
        • 10.4.6.1.1. Market Opportunities and Trends
        • 10.4.6.1.2. Growth Prospects
      • 10.4.6.2. Germany
        • 10.4.6.2.1. Market Opportunities and Trends
        • 10.4.6.2.2. Growth Prospects
      • 10.4.6.3. France
        • 10.4.6.3.1. Market Opportunities and Trends
        • 10.4.6.3.2. Growth Prospects
      • 10.4.6.4. Italy
        • 10.4.6.4.1. Market Opportunities and Trends
        • 10.4.6.4.2. Growth Prospects
      • 10.4.6.5. Spain
        • 10.4.6.5.1. Market Opportunities and Trends
        • 10.4.6.5.2. Growth Prospects
      • 10.4.6.6. Others
        • 10.4.6.6.1. Market Opportunities and Trends
        • 10.4.6.6.2. Growth Prospects
  • 10.5. Middle East and Africa
    • 10.5.1. By Product Type
    • 10.5.2. By Target Type
    • 10.5.3. By Technology
    • 10.5.4. By Application
    • 10.5.5. By End-User
    • 10.5.6. By Country
      • 10.5.6.1. Saudi Arabia
        • 10.5.6.1.1. Market Opportunities and Trends
        • 10.5.6.1.2. Growth Prospects
      • 10.5.6.2. UAE
        • 10.5.6.2.1. Market Opportunities and Trends
        • 10.5.6.2.2. Growth Prospects
      • 10.5.6.3. Others
        • 10.5.6.3.1. Market Opportunities and Trends
        • 10.5.6.3.2. Growth Prospects
  • 10.6. Asia Pacific
    • 10.6.1. By Product Type
    • 10.6.2. By Target Type
    • 10.6.3. By Technology
    • 10.6.4. By Application
    • 10.6.5. By End-User
    • 10.6.6. By Country
      • 10.6.6.1. Japan
        • 10.6.6.1.1. Market Opportunities and Trends
        • 10.6.6.1.2. Growth Prospects
      • 10.6.6.2. China
        • 10.6.6.2.1. Market Opportunities and Trends
        • 10.6.6.2.2. Growth Prospects
      • 10.6.6.3. India
        • 10.6.6.3.1. Market Opportunities and Trends
        • 10.6.6.3.2. Growth Prospects
      • 10.6.6.4. South Korea
        • 10.6.6.4.1. Market Opportunities and Trends
        • 10.6.6.4.2. Growth Prospects
      • 10.6.6.5. Taiwan
        • 10.6.6.5.1. Market Opportunities and Trends
        • 10.6.6.5.2. Growth Prospects
      • 10.6.6.6. Thailand
        • 10.6.6.6.1. Market Opportunities and Trends
        • 10.6.6.6.2. Growth Prospects
      • 10.6.6.7. Indonesia
        • 10.6.6.7.1. Market Opportunities and Trends
        • 10.6.6.7.2. Growth Prospects
      • 10.6.6.8. Others
        • 10.6.6.8.1. Market Opportunities and Trends
        • 10.6.6.8.2. Growth Prospects

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 11.1. Major Players and Strategy Analysis
  • 11.2. Market Share Analysis
  • 11.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 11.4. Competitive Dashboard

12. COMPANY PROFILES

  • 12.1. The Linde Group
  • 12.2. Astrazeneca
  • 12.3. Pfizer, Inc
  • 12.4. Seagen, Inc.
  • 12.5. GSK Plc
  • 12.6. Takeda Pharmaceutical Company Ltd.
  • 12.7. F. Hoffmann-La Roche Ltd.
  • 12.8. Novartis
  • 12.9. Gilead Sciences, Inc.
  • 12.10. Sanofi S.A.
  • 12.11. Astellas Pharma
  • 12.12. Daiichi Sankyo Company Ltd.
  • 12.13. Genentech Inc.
  • 12.14. Immunogen Inc.
  • 12.15. Lantheus
  • 12.16. Bayer Healthcare Pharmaceuticals
  • 12.17. Astellas Pharma
  • 12.18. Synthon Holding BV